



22 September 2016

Dr Thomas Salmonson  
Chair CHMP, MPA  
European Medicines Agency  
7 Westferry Circus  
Canary Wharf  
London  
E14 4HB  
United Kingdom

**Subject: Withdrawal of Pemetrexed (as ditromethamine) Hospira 100mg/500mg/1,000mg powder for concentrate for solution for infusion - EMEA/H/C/0004306**

Dear Dr Salmonson,

I would like to inform you that, at this point of time, Hospira UK Limited has taken the decision to withdraw the application for Marketing Authorisation of **Pemetrexed (as ditromethamine) Hospira 100mg/500mg, 1,000mg powder for concentrate for solution for infusion**, which was intended to be used in the treatment of malignant pleural mesothelioma and non-small cell lung cancer.

This withdrawal is due to a change in Hospira UK Limited's commercial strategy.  
There are no consequences of the withdrawal and there are no ongoing clinical trials or compassionate use programmes.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,